Avances contra el glioblastoma de Laminar Pharma

from Biotecnología Capital · host Capital Radio

La directora científica de Laminar Pharma, Paula Fernández, no cuenta los últimos avances en su fármaco LAM561 contra el glioblastoma, uno de los tipos de cáncer en el cerebro que menos esperanza de vida tiene.

Episode metadata supplied by the publisher feed · Published Apr 3, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

Avances contra el glioblastoma de Laminar Pharma

0:00 24:56

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Biotecnología Capital?

This episode is 24 minutes long.

When was this Biotecnología Capital episode published?

This episode was published on April 3, 2024.

Can I download this Biotecnología Capital episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!